
AstraZeneca and partner Bristol-Myers Squibb have been granted a priority review for their rare disease drug metreleptin. The medicine is …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

